New Human iPSC-Derived Astrocytes now available from Axol Bioscience.
These Astrocytes are cryopreserved for convenience, they are ready to use and assay ready within 48 hrs. Once thawed, Axol's Astrocytes display all indicative markers and will respond to glutamate stimulation, a key functional characteristic within 48-60hrs. They also express markers showing that Axol's Human iPSC-Derived Astrocytes are physiologically representative of human primary astrocytes.
These are derived from integration-free, induced pluripotent stem cells (iPSCs) under fully defined growth conditions using a completely reproducible process to enable researchers to gain further insight into the mechanisms that govern CNS development, disease onset and drug response.
Astrocyte dysfunction has been implicated in a number of neurological conditions such as Alzheimer’s and Parkinson’s diseases, autism, amyotrophic lateral sclerosis (ALS), Rett syndrome and schizophrenia.
Axol’s Human iPSC-derived Astrocytes offer a convenient and physiologically-relevant tool to study these cells as an isolated population or within co-culture and multiple culture populations with other neuronal cells for complex analysis of the central nervous system (CNS).
Axol's Human iPSC-Derived Astrocytes express prototypical phenotype markers such as glial fibrillary acidic protein (GFAP), S100b, AQP4, ALDHL1L and EAAT1.
These Astrocytes have also been further validated where they display other key biomarkers including Vimentin, Kir4.1 (potassium channel) and CD44.
Huntington's Disease-specific iPSC-derived Neural Stem Cells (CAG 50); > 1.5 million cells per vial.